HRP20140706T1 - Sastavi viralnih inhibitora za in vivo terapeutsku upotrebu koji ukljuäśuju kombinaciju (-)-karvona, (+)-karvona, geraniola i daljnju komponentu esencijalnog ulja - Google Patents

Sastavi viralnih inhibitora za in vivo terapeutsku upotrebu koji ukljuäśuju kombinaciju (-)-karvona, (+)-karvona, geraniola i daljnju komponentu esencijalnog ulja Download PDF

Info

Publication number
HRP20140706T1
HRP20140706T1 HRP20140706AT HRP20140706T HRP20140706T1 HR P20140706 T1 HRP20140706 T1 HR P20140706T1 HR P20140706A T HRP20140706A T HR P20140706AT HR P20140706 T HRP20140706 T HR P20140706T HR P20140706 T1 HRP20140706 T1 HR P20140706T1
Authority
HR
Croatia
Prior art keywords
human
composition
disease
carvone
virus
Prior art date
Application number
HRP20140706AT
Other languages
English (en)
Inventor
Christine Coppens
Original Assignee
Cesa Alliance S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42102951&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20140706(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cesa Alliance S.A. filed Critical Cesa Alliance S.A.
Publication of HRP20140706T1 publication Critical patent/HRP20140706T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • A61K31/085Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/14Quaternary ammonium compounds, e.g. edrophonium, choline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (6)

1. Sastav koji se sastoji od (-)-Karvona i (+)-Karvona i Trans-Geraniola i barem još jedne komponente izabrane od Eugenol metiletera i Linalooloksida i (cis+trans)-1,2-(+)-Limonen oksida i Lavendulola u farmaceutski učinkovitoj koncentraciji za upotrebu u liječenju i prevenciji bolesti uzrokovanih virusima obavijenim sa DNK, virusima neobavijenim sa DNK, virusima obavijenim sa RNK, virusima neobavijenim sa DNK, koje bolesti su odabrane iz skupine koja se sastoji od: (bronho)-pneumonije, 3-dnevne groznice egzantema, akutnog i kroničnog hepatitisa, akutne groznice, akutnog gastroenteritisa uzrokovanog naporima kao što je Desert Shield Lordsdale Mexico Norwalk Hawaii Snow Mountain Southampton virus, akutnog gastroenteritisa uzrokovanog naporima kao što je Houston/86 Houston/90 London 29845 Manchester Parkville Sapporo virus, akutnog hepatitisa, sindroma akutne respiratorne boli, AIDS-a, argentinske hemoragijske groznice, artralgije, ptičje gripe, bolivijske hemoragijske groznice, brazilske hemoragijske groznice, vodenih kozica, kroničnog hepatitisa, kome, infekcije prehladom, simptoma prehlade, kongenitalne infekcije, konjuktivitisa, zarazne ektime, zaraznog bubuljičavog dermatitisa, rožnjače, kriptične tifusne infekcije, citomegalovirusne mononukleoze, denga hemoragijske groznice (DHF), denga šok sindroma (DSS), proljeva, egzema, egzema herpatikum, encefalitisa, encefalopatije, enteritisa, epidemijske nefropatije, epidemijskog poliartritisa i egzantema, epidermodisplazije veruciformis, Epstein-Barr virusne infekcije, egzantema, egzantema kod djece, fatalne obiteljske insomnije, febrilnog encefalitisa, febrilne bolesti, groznice, nekadašnjeg humanog echo virusa 22 23, gastroenteritisa, gastrointestinalnih infekcija intracitoplazmičkim uključujućim tijelima, infekcija genitalnog trakta, hemolitičke krize kod ljudi sa bolešću srpastih stanica, glavobolja, hemoragijske groznice, hemoragijske groznice sa renalnim sindromom, herpesnog encefalitisa, Hodgkinove bolesti, humanog koksaki virusa, humanog koksaki virusa B1-6, humanog echo virusa 1-7 9 11-21 24-27 29-33, humanog enterovirusa 69, humanog enterovirusa 71 (bolest ruku, stopala i usta), humanog virusa hepatitisa A (HHAV), humanog polio virusa, humanog rinovirusa 1 2 7 9 11 15 16 21 29 36 39 49 50 58 62 65 85 89, hiperakutne respiratorne bolesti, humanog rinovirusa 3 14 72, hiperakutne respiratorne bolesti, sindroma imunodeficijencije, infantilnog proljeva, infekcije sa bilo kojim denga serotipom (1-4), infektivne mononukleoze, bolova u zglobovima, Kaposijevog sarkoma, keratokonjuktivitisa, lezija kutanoznih područja, leukopenije, ciroze jetre, infekcije donjeg dišnog trakta, limfadenopatije, makulopapularnog osipa, ospica, meningitisa, mononukleoze (bolesti ljubljenja), zaušnjaka, bolova mišića, miokarditisa, nefropatije, nefropatije kod transplantiranih pacijenata, obamrlosti, oportunističke infekcije, oralnih infekcija, orkitisa, pankreatitisa, pandemika, papiloma, paralize, otporne infekcije bubrega, otpornih infekcija, otporne limfopatije, faringealnog konjuktivitisa, upale pluća, primarnog hepatocelularnog karcinoma, pulmonarnog sindroma, bjesnoće, osipa, recidivne epidemije respiratorne bolesti, respiratorne bolesti, respiratornih oboljenja, rozeole infantum, sarkoma, ozbiljne artralgije s drhtavicom, ozbiljnog akutnog respiratornog sindroma, ozbiljnog encefalitisa, herpes zostera, šeste bolesti, lezija kože i mukozne membrane, bolesti mršavljenja, bolnog grla, subakutnog skleroznog panencefalitisa, superinfekcije sa Deltavirusom, ulceracije, bolesti gornjeg dišnog trakta, venecuelanske hemoragijske groznice, vezikularnog faringitisa, vezikularnog stomatitisa sa egzantemom, virusnog poliartritisa i navale, virusnih bradavica, vodenog proljeva, slabosti, zoonotika, zostera, metaplazije, displazije, anaplazije, dezmoplazije, in situ karcinoma, gripe (influence), invazivnog karcinoma.
2. Sastav za upotrebu temeljem zahtjeva 1, pri čemu se sastav koristi kao profilaktik.
3. Sastav za upotrebu temeljem zahtjeva 1, pri čemu se sastav koristi kao virusni inhibitor unutar tijela.
4. Sastav za upotrebu temeljem zahtjeva 1, pri čemu se sastav daje, oralno, topikalno, inhalacijom, supozitorijem, intravenozno, potkožno ili intramuskularno.
5. Upotreba sastava temeljem zahtjeva 1 kao dezinficijensa.
6. Upotreba sastava temeljem zahtjeva 1 kao virusnog inhibitora izvan tijela.
HRP20140706AT 2010-03-26 2014-07-22 Sastavi viralnih inhibitora za in vivo terapeutsku upotrebu koji ukljuäśuju kombinaciju (-)-karvona, (+)-karvona, geraniola i daljnju komponentu esencijalnog ulja HRP20140706T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10157930A EP2368547B1 (en) 2010-03-26 2010-03-26 Antiviral compositions comprising geraniol and carvone
PCT/EP2011/054758 WO2011117424A1 (en) 2010-03-26 2011-03-28 Viral inhibitor compositions for in vivo therapeutic use comprising a combination of (-) -carvone, geraniol and a further essential oil component

Publications (1)

Publication Number Publication Date
HRP20140706T1 true HRP20140706T1 (hr) 2014-09-12

Family

ID=42102951

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20120964AT HRP20120964T1 (en) 2010-03-26 2012-11-27 Antiviral compositions comprising geraniol and carvone
HRP20140706AT HRP20140706T1 (hr) 2010-03-26 2014-07-22 Sastavi viralnih inhibitora za in vivo terapeutsku upotrebu koji ukljuäśuju kombinaciju (-)-karvona, (+)-karvona, geraniola i daljnju komponentu esencijalnog ulja

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20120964AT HRP20120964T1 (en) 2010-03-26 2012-11-27 Antiviral compositions comprising geraniol and carvone

Country Status (35)

Country Link
US (2) US8980945B2 (hr)
EP (2) EP2368547B1 (hr)
JP (1) JP5342085B2 (hr)
KR (1) KR101340260B1 (hr)
CN (1) CN102946876B (hr)
AU (1) AU2011231511B2 (hr)
BR (1) BR112012024260B1 (hr)
CA (1) CA2790087C (hr)
CL (1) CL2012002606A1 (hr)
CO (1) CO6602166A2 (hr)
CY (3) CY1113449T1 (hr)
DK (2) DK2368547T3 (hr)
EA (1) EA025278B9 (hr)
ES (2) ES2392938T3 (hr)
HK (1) HK1176019A1 (hr)
HR (2) HRP20120964T1 (hr)
HU (1) HUE026121T2 (hr)
IL (1) IL222048A (hr)
LU (1) LU91805B1 (hr)
MA (1) MA34074B1 (hr)
ME (1) ME02035B (hr)
MX (1) MX346412B (hr)
MY (2) MY153104A (hr)
NZ (1) NZ602602A (hr)
PE (2) PE20130065A1 (hr)
PL (2) PL2368547T3 (hr)
PT (2) PT2368547E (hr)
RS (2) RS52544B (hr)
SG (1) SG184039A1 (hr)
SI (2) SI2368547T1 (hr)
SM (2) SMT201200062B (hr)
TN (2) TN2012000444A1 (hr)
UA (1) UA102497C2 (hr)
WO (1) WO2011117424A1 (hr)
ZA (2) ZA201208116B (hr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013064360A2 (en) 2011-11-03 2013-05-10 Unilever N.V. A personal cleaning composition
CN104023539B (zh) 2011-12-06 2021-08-13 联合利华知识产权控股有限公司 抗微生物组合物
JP2015505835A (ja) 2011-12-06 2015-02-26 ユニリーバー・ナームローゼ・ベンノートシヤープ 抗菌性組成物
BR112014013601B1 (pt) 2011-12-06 2020-04-14 Unilever Nv composições antimicrobianas, método não terapêutico para desinfetar uma superfície e usos não terapêuticos de uma composição
MX347951B (es) 2012-06-27 2017-05-19 Unilever Nv Composicion antimicrobiana.
RU2533254C2 (ru) * 2012-12-29 2014-11-20 Федеральное государственное бюджетное учреждение научно-исследовательский институт детских инфекций Федерального медико-биологического агентства Способ лечения неврологических осложнений при ветряной оспе у детей
TWI463979B (zh) * 2013-04-12 2014-12-11 Nat Defense Medical Ct 檸檬醛用於製備治療局部腎絲球硬化症之藥物的用途
KR20150145314A (ko) 2014-06-18 2015-12-30 원광대학교산학협력단 카르본을 유효성분으로 포함하는 항균 조성물
CN106727628A (zh) * 2016-12-17 2017-05-31 郑州郑先医药科技有限公司 一种治疗慢性腹泻的西药组合物
KR101970281B1 (ko) * 2017-07-28 2019-04-18 고려대학교 산학협력단 리나릴 아세테이트를 포함하는 올메사탄으로 유발된 장운동과다증의 예방 또는 치료용 조성물
CN107648488A (zh) * 2017-09-29 2018-02-02 陈晓阳 一种用于治疗慢性咽炎的丸剂
KR102118181B1 (ko) * 2018-06-12 2020-06-02 광주여자대학교 산학협력단 식물성 정유를 유효성분으로 포함하는 a형 인플루엔자 바이러스에 대한 항바이러스 조성물
RU2707950C1 (ru) * 2018-11-28 2019-12-02 Общество с ограниченной ответственностью "ЭРБИ" Средство для обработки среды пребывания птицы на основе липосом с фитокомпозицией с иммунотропным действием и избирательным антисептическим эффектом и способ его применения
US20200179299A1 (en) * 2018-12-07 2020-06-11 Global Biolife Inc. Composition and method of controlling infectious diseases with functional fragrances
CN110496117B (zh) * 2019-09-30 2022-09-06 中国科学院微生物研究所 一种小分子化合物在抗非洲猪瘟病毒感染中的新应用
CN111012769B (zh) * 2019-12-05 2021-02-12 青海大学 一种用于治疗包虫病的药物组合物、药物制剂及乳剂制备方法
SG10201914042SA (en) * 2019-12-31 2021-07-29 Xj Bio Engineering Int Pte Ltd Feed additive for preventing african swine fever disease or replacing antibiotic growth promoters and methods of making and using the same
WO2021224947A1 (en) * 2020-05-02 2021-11-11 Norouzi Mehdi Formulation of acute respiratory disease control formulation
CN114716327A (zh) * 2020-12-14 2022-07-08 中南民族大学 柏木醇衍生物、其制备方法及其应用
CA3102947A1 (en) * 2020-12-18 2022-06-18 Skymount Medical Us Inc. Nutraceuticals useful in the treatment of coronavirus diseases
CN115141681B (zh) * 2021-03-30 2024-06-21 湖南诺泽生物科技有限公司 挥发油、其制备方法及用途
JP7133820B1 (ja) 2021-06-09 2022-09-09 塩野香料株式会社 コロナウイルス感染症予防用香料組成物及び結合阻害剤
CN113994963B (zh) * 2021-09-26 2023-04-28 中国农业科学院烟草研究所(中国烟草总公司青州烟草研究所) 一种含有乙酸二氢香芹酯的抑芽剂及其用途
TWI800937B (zh) * 2021-10-01 2023-05-01 奇美醫療財團法人奇美醫院 用於治療登革熱病毒感染之方法
WO2024097158A1 (en) * 2022-11-01 2024-05-10 Ramirez Christina M Viral prophylaxis treatment methods and pre-exposure prophylaxis kits
CN117338758B (zh) * 2023-12-06 2024-03-12 北京远大九和药业有限公司 一种药物组合物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5667M (hr) 1966-03-10 1968-01-02
LU78955A1 (de) * 1978-01-27 1979-09-06 Chimicasa Gmbh Verfahren zur inaktivierung von viren
US4902678A (en) * 1982-02-12 1990-02-20 Syntex (U.S.A.) Inc. Anti-viral compositions
US5856364A (en) * 1991-03-01 1999-01-05 Warner Lambert Company Therapeutic antiviral-wound healing compositions and methods for preparing and using same
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
AU2002217316A1 (en) * 2001-01-03 2002-07-30 Medpharma Plc Use of terpenes for the treatment of digestive tract infections
US20040071757A1 (en) * 2001-11-20 2004-04-15 David Rolf Inhalation antiviral patch
JP6027718B2 (ja) * 2005-11-30 2016-11-16 エーデン リサーチ ピーエルシー チモール、オイゲノール、ゲラニオール、シトラール、及びl−カルボンから選択されたテルペン又はテルペン混合物を含む組成物及び方法
US9403126B2 (en) * 2007-01-10 2016-08-02 The Regents Of The University Of Michigan Ultrafiltration membrane, device, bioartificial organ, and related methods
KR100796312B1 (ko) * 2007-05-23 2008-01-21 주식회사 바이오미스트테크놀로지 게라니얼,네랄 및 유게놀을 유효성분으로 함유하는 동물용소독제 조성물
KR100941595B1 (ko) 2008-06-05 2010-02-11 주식회사 알앤엘바이오 바이러스 억제제로서 유용한 트리테르페노이드계 화합물
KR100950428B1 (ko) 2008-06-05 2010-04-02 주식회사 알앤엘바이오 바이러스 억제제로서 유용한 디아릴헵타노이드계 화합물

Also Published As

Publication number Publication date
RS53435B (en) 2014-12-31
SI2555763T1 (sl) 2014-08-29
AU2011231511B2 (en) 2014-03-20
KR101340260B1 (ko) 2013-12-10
TN2012000444A1 (en) 2014-01-30
EA025278B1 (ru) 2016-12-30
EP2368547A1 (en) 2011-09-28
PT2368547E (pt) 2012-11-20
PE20130065A1 (es) 2013-03-08
AU2011231511A1 (en) 2012-10-18
CN102946876B (zh) 2016-04-06
PL2555763T3 (pl) 2014-09-30
CN102946876A (zh) 2013-02-27
CY1119841T1 (el) 2018-06-27
SI2368547T1 (sl) 2013-01-31
CO6602166A2 (es) 2013-01-18
WO2011117424A1 (en) 2011-09-29
PE20141008A1 (es) 2014-09-20
EP2555763B1 (en) 2014-04-30
HRP20120964T1 (en) 2012-12-31
JP2013523622A (ja) 2013-06-17
CL2012002606A1 (es) 2013-10-18
EA201270749A1 (ru) 2013-03-29
US8883859B1 (en) 2014-11-11
BR112012024260A2 (pt) 2016-07-12
TN2013000366A1 (en) 2015-01-20
ME02035B (me) 2013-04-30
DK2555763T3 (da) 2014-08-04
MA34074B1 (fr) 2013-03-05
NZ602602A (en) 2012-12-21
EA025278B9 (ru) 2017-03-31
US20130225676A1 (en) 2013-08-29
CA2790087A1 (en) 2011-09-29
IL222048A (en) 2014-09-30
EP2368547B1 (en) 2012-09-12
BR112012024260B1 (pt) 2019-12-31
ES2392938T3 (es) 2012-12-17
EP2555763A1 (en) 2013-02-13
US8980945B2 (en) 2015-03-17
CY1113449T1 (el) 2016-06-22
HUE026121T2 (en) 2016-05-30
RS52544B (en) 2013-04-30
CY1115375T1 (el) 2017-01-04
ZA201208116B (en) 2014-04-30
PL2368547T3 (pl) 2013-02-28
UA102497C2 (ru) 2013-07-10
DK2368547T3 (da) 2013-01-02
CA2790087C (en) 2013-07-30
HK1176019A1 (en) 2013-07-19
MX346412B (es) 2017-03-17
PT2555763E (pt) 2014-08-04
ES2486765T3 (es) 2014-08-19
JP5342085B2 (ja) 2013-11-13
MY158757A (en) 2016-11-15
LU91805B1 (fr) 2011-09-26
SMT201400104B (it) 2014-09-08
SG184039A1 (en) 2012-10-30
MY153104A (en) 2014-12-31
MX2012010949A (es) 2013-01-29
KR20120128716A (ko) 2012-11-27
SMT201200062B (it) 2013-03-08
ZA201306926B (en) 2014-04-30

Similar Documents

Publication Publication Date Title
HRP20140706T1 (hr) Sastavi viralnih inhibitora za in vivo terapeutsku upotrebu koji ukljuäśuju kombinaciju (-)-karvona, (+)-karvona, geraniola i daljnju komponentu esencijalnog ulja
RU2019118390A (ru) Производное пиразоло-гетероарила, способ его получения и медицинское применение
Clercq Antivirals and antiviral strategies
DE602006015861D1 (de) Antivirale verbindungen
ATE538810T1 (de) Funktionale influenza-virus-ähnliche teilchen (vlps)
EA035439B1 (ru) Амидное соединение и его применение в качестве средства для лечения и профилактики заболеваний, вызываемых рнк- и/или днк-содержащими вирусами, и сопутствующих заболеваний
Hersoug Viruses as the causative agent related to ‘dampness’ and the missing link between allergen exposure and onset of allergic disease.
de Patología Digestiva et al. Recommendations by the SEPD and AEG, both in general and on the operation of gastrointestinal endoscopy and gastroenterology units, concerning the current SARS-CoV-2 pandemic (March, 18)
CN118076589A (zh) 一种酰胺类化合物、其制备方法和制药用途
HRP20150596T1 (hr) Sastav viralnih inhibitora za in vivo terapeutsku upotrebu
JP2022551458A (ja) ハンタウイルス感染症の処置のためのmek阻害剤
Parvez Gut feeling: the plausible fecal-oral transmission route of COVID-19
Mizuta et al. Phylogenetic and cluster analysis of human rhinovirus species A (HRV-A) isolated from children with acute respiratory infections in Yamagata, Japan
Kaiser et al. Editorial response: rhinovirus pneumonia: a clinical entity?
EA201490025A1 (ru) Производные 1,3-диоксоиндена, их фармацевтически приемлемая соль, способ их получения и фармацевтическая антивирусная композиция, содержащая их в качестве активного ингредиента
Chertow et al. Influenza, Measles, SARS, MERS, and Smallpox
Jhawar Severe bronchiolitis in children
Oh Trend in viral infectious diseases in children
Abdo et al. Fatal 2009 pandemic influenza A (H1N1) in a bone marrow transplant recipient
Rodriguez Covid-19: A fecal-orally transmitted disease with severe involvement of the lungs
Cruz-Jiménez et al. An Overview of Antivirals for Treating Lower Respiratory Tract Infections
Lee et al. A study about the relation between elevated transaminase level and severity of viral lower respiratory tract infection in children
Tarrass Avian pandemic: Is there a potential concern for nephrologists?
Kang et al. Epidemiology of acute viral resp iratory tract infections in Busan (2004–2006)
Clement et al. Hantaviral infections